PMC5846910_01
Computed tomography scans, from left to right, showing a pelvic target lesion (1) at baseline measuring 20.3 mm largest diameter, (2) after 1 month of RRx-001 treatment measuring 22.6 largest diameter, and (3) after 2 cycles of carboplatin-taxane measuring 10.8 mm largest diameter.
10.1177_2324709618760080-fig1.jpg
PMC5846910_01_10.1177_2324709618760080-fig1.jpg
fig1-2324709618760080
After Cycle 1 of carbo-taxane her CA-125 decreased to 1600. At the end of Cycle 2 on May 23, 2017, despite detection of an asymptomatic pulmonary embolism for which the factor Xa inhibitor, apaxiban (Eliquis) was started, the patient was exhibiting radiographic, biochemical, and symptomatic improvement: target lesions were significantly smaller (computed tomography images shown in Figure 1), resulting in a partial response; her CA-125 was 830 (lower than baseline of 1200); and her abdominal pain had entirely disappeared, resulting in voluntary discontinuation from all opioid medications.